Overview

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Status:
Unknown status

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

It is a phase III trial to explore the efficacy and safety of vinorelbine plus capecitabine (NX) and docetaxel plus capecitabine (TX) as first line treatment followed by capecitabine alone till Progressive Disease(PD). We plan to enroll 200 pts for limited budget and the non-inferior trend of the two curves is anticipated.

Phase:

Phase 3

Details

Lead Sponsor:

Chinese Academy of Medical Sciences

Collaborator:

Hoffmann-La Roche

Treatments:

Capecitabine
Docetaxel
Vinblastine
Vinorelbine